Showing results (2391-2400 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|July 27, 2025
Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for ObesityBecky Pennington, Ewen Cummins, Albany Chandler, et al.Pharmacoeconomics|April 27, 2025
Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and FranceMicha J Pilz, Simone Seyringer, Virginie Nerich, et al.Pharmacoeconomics|April 29, 2025
Cost-Effectiveness Analysis Methods Used in Evaluations of Treatment for Cystic Fibrosis: A Scoping ReviewDominique Seo, David C Young, Eberechukwu Onukwugha, et al.Pharmacoeconomics|April 28, 2025
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic ReviewKatharina Abraham, Isaac Corro Ramos, C Louwrens Braal, et al.Pharmacoeconomics|September 8, 2025
Highlights from the Manifesto on the Health Economics of Cardiovascular Disease PreventionZanfina Ademi, Sheridan E Rodda, Karl Vivoda, et al.Pharmacoeconomics|August 18, 2025
Lifetime Healthcare and Long-Term Care Costs of Heart Failure: Estimates Using Administrative Data from Hospitalized Patients in the NetherlandsHamraz Mokri, Pieter van Baal, Maureen Rutten-van MölkenPharmacoeconomics|August 12, 2025
Bayesian Cost-Effectiveness Analysis Using Individual-Level Data is Sensitive to the Choice of Uniform Priors on the Standard Deviations for Costs in Log-Normal ModelsXiaoxiao Ling, Andrea Gabrio, Gianluca BaioPharmacoeconomics|February 16, 2026
The Cost Effectiveness of Upgrading Cochlear Implant Sound Processors in Australia: A Novel Application of Individual-Level Microsimulation ModelsBonny Parkinson, Elizabeth Seil, Rajan Sharma, et al.Pharmacoeconomics|August 21, 2012
Private manufacturers' thresholds to invest in comparative effectiveness trialsAnirban Basu, David MeltzerPharmacoeconomics|February 6, 2026
A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost PerspectivesJosep Darbà, Meritxell Ascanio, Antonio RodríguezPageof 336